The GLYT1 inhibitor bitopertin mitigates erythroid PPIX production and liver disease in erythroid protoporphyria

Sarah Ducamp, Min Wu, Juan Putra, Dean R. Campagna, Xiang Yi, Vu Hong, Matthew M. Heeney, Amy K. Dickey, Rebecca Karp Leaf, Mark D. Fleming, Brian MacDonald, Paul J. SchmidtJournal of Clinical Investigation 2025 · DOI

Abstract

Erythropoietic protoporphyria (EPP) is a genetic disorder typically resulting from decreased ferrochelatase (FECH) activity, the last enzyme in heme biosynthesis. Patients with X-linked protoporphyria (XLPP) have an overlapping phenotype caused by increased activity of 5-aminolevulinic acid synthase 2 (ALAS2), the first enzyme in erythroid heme synthesis. In both cases, protoporphyrin IX (PPIX) accumulates in erythrocytes and secondarily in plasma and tissues. Patients develop acute phototoxicity reactions upon brief exposure to sunlight. Some also experience chronic liver disease, and a small fraction develop acute cholestatic liver failure. Therapeutic options are limited, and none, save hematopoietic stem cell transplantation, directly targets erythroid PPIX accumulation. Bitopertin is an investigational orally available small-molecule inhibitor of the erythroid cell-surface glycine transporter GLYT1. We established the bitopertin PPIX inhibitory half-maximal effective concentration in a human erythroblast EPP model and confirmed a marked reduction of PPIX in erythroblasts derived from patients with EPP. We demonstrate that bitopertin also reduced erythrocyte and plasma PPIX accumulation in vivo in both EPP and XLPP mouse models. Finally, the reduction in erythroid PPIX ameliorated liver disease in the EPP mouse model. Altogether, these data support the development of bitopertin to treat patients with EPP or XLPP.

Introduction

Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLPP) are rare genetic disorders characterized by a critical imbalance in the heme biosynthetic pathway. In EPP, a deficiency in ferrochelatase (FECH) creates a bottleneck at the final step of heme production. Conversely, XLPP is driven by gain-of-function mutations in ALAS2, causing the pathway to overproduce intermediates. Both conditions result in the massive accumulation of protoporphyrin IX (PPIX) in red blood cells.

PPIX is a potent photoactive toxin. When exposed to light in the skin's microvasculature, it generates reactive oxygen species, leading to severe phototoxicity characterized by excruciating pain and skin damage. Beyond skin symptoms, the liver's role in clearing excess PPIX can lead to chronic liver disease and, in severe cases, fatal acute cholestatic liver failure. Current management strategies primarily address symptoms rather than the underlying metabolic defect. This study explores bitopertin, an oral inhibitor of the glycine transporter GLYT1, as a novel therapeutic to reduce PPIX production at its source.

Methods and Model Validation

To evaluate bitopertin, researchers utilized a combination of cellular and animal models. A primary tool was a human erythroleukemic cell line (K562) engineered via CRISPR/Cas9 to mimic the common EPP-associated splicing defect ($c.315-48T>C$). This mutation leads to aberrant splicing of FECH mRNA and a subsequent loss of enzyme activity.

Validation of the K562-EPP cellular model showing aberrant splicing and significant PPIX accumulation.

As shown in Figure 1, the engineered K562-EPP cells successfully recapitulated the disease phenotype. Panel A and B demonstrate the aberrant splicing mechanism and the presence of abnormal RNA transcripts. Panels C and D confirm that these cells accumulate high levels of PPIX (~400 pmol/10^6 cells) compared to wild-type K562 cells, where PPIX is below the limit of quantification.

The study also employed:

  • Patient-Derived Cells: CD34+ hematopoietic stem cells from three EPP patients, differentiated into erythroblasts.
  • Animal Models: $Fech^{m1PAS}$ (EPP) and $Alas2^{Gln548*}$ (XLPP) mouse models.
  • Analytical Techniques: Glycine uptake was measured using $^3$H-glycine, and PPIX levels were quantified via flow cytometry and UPLC.

Key Insights: Restricting the Glycine Supply

The therapeutic rationale for bitopertin hinges on the fact that heme synthesis requires eight molecules of glycine for every molecule of heme produced. By inhibiting GLYT1, the primary glycine transporter in erythroid precursors, bitopertin restricts the availability of this essential substrate. This effectively "turns down the tap" on the entire heme biosynthetic pathway, preventing the pathological accumulation of PPIX.

Crucially, GLYT1 expression is highly specific to the brain and erythroid cells. This specificity allows bitopertin to target heme synthesis in developing red blood cells without broadly impacting other tissues. In mouse models, the reduction in PPIX was rapid, appearing in reticulocytes within 24 hours of treatment initiation.

Results

Bitopertin demonstrated high potency and significant disease-modifying effects:

  • In Vitro Potency: The $EC_{50}$ for PPIX inhibition in human erythroblasts was 32 nM.
  • In Vivo PPIX Reduction: In both EPP and XLPP mouse models, bitopertin treatment reduced red blood cell PPIX levels by 30% to 40%.
  • Liver Protection: Most significantly, bitopertin treatment in the EPP mouse model led to a marked reduction in liver pathology. This included a significant decrease in the incidence of ductular reactions ($P = 0.0083$) and the severity of liver fibrosis ($P = 0.0023$).
  • Safety: While bitopertin caused a minor, dose-dependent decrease in hemoglobin levels—an expected result of slowing heme synthesis—this effect was clinically negligible and did not lead to severe anemia.

Conclusion and Future Directions

This study provides strong preclinical evidence that GLYT1 inhibition via bitopertin can effectively reduce the toxic accumulation of PPIX and mitigate associated liver disease in EPP and XLPP. While the $Fech^{m1PAS}$ mouse model represents a particularly severe form of the disease, the consistent reduction in PPIX across multiple models is promising.

The primary limitation of this study is the lack of direct phototoxicity measurements in mice, although PPIX reduction is a well-accepted surrogate marker for clinical improvement in patients. The true clinical utility of bitopertin is currently being evaluated in human trials, with a Phase III trial (APOLLO) anticipated to provide definitive efficacy data in 2025.

Summary updated

Abstract

Erythropoietic protoporphyria (EPP) is a genetic disorder typically resulting from decreased ferrochelatase (FECH) activity, the last enzyme in heme biosynthesis. Patients with X-linked protoporphyria (XLPP) have an overlapping phenotype caused by increased activity of 5-aminolevulinic acid synthase 2 (ALAS2), the first enzyme in erythroid heme synthesis. In both cases, protoporphyrin IX (PPIX) accumulates in erythrocytes and secondarily in plasma and tissues. Patients develop acute phototoxicity reactions upon brief exposure to sunlight. Some also experience chronic liver disease, and a small fraction develop acute cholestatic liver failure. Therapeutic options are limited, and none, save hematopoietic stem cell transplantation, directly targets erythroid PPIX accumulation. Bitopertin is an investigational orally available small-molecule inhibitor of the erythroid cell-surface glycine transporter GLYT1. We established the bitopertin PPIX inhibitory half-maximal effective concentration in a human erythroblast EPP model and confirmed a marked reduction of PPIX in erythroblasts derived from patients with EPP. We demonstrate that bitopertin also reduced erythrocyte and plasma PPIX accumulation in vivo in both EPP and XLPP mouse models. Finally, the reduction in erythroid PPIX ameliorated liver disease in the EPP mouse model. Altogether, these data support the development of bitopertin to treat patients with EPP or XLPP.
BibTeX
@article{ducamp2025glyt,
  author = {Sarah Ducamp and Min Wu and Juan Putra and Dean R. Campagna and Xiang Yi and Vu Hong and Matthew M. Heeney and Amy K. Dickey and Rebecca Karp Leaf and Mark D. Fleming and Brian MacDonald and Paul J. Schmidt},
  title = {{The GLYT1 inhibitor bitopertin mitigates erythroid PPIX production and liver disease in erythroid protoporphyria}},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci181875},
}
Figure